Ondansetron Orally Disintegrating Tablets — Class II drug recall D-0246-2026
Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2026-01-07, distributed nationwide. Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blis
| Recall number | D-0246-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ, United States |
| Recall initiated | 2025-12-30 |
| Classified | 2025-12-31 |
| Reported by FDA | 2026-01-07 |
| Distributed | Nationwide (US) |
| Quantity | 96,948 packages |
| Reason classes | packaging |
| NDC | 68462-0105, 68462-0105-30, 68462-0105-33, 68462-0106, 68462-0106-30, 68462-0106-33, 68462-0157, 68462-0157-13, 68462-0158, 68462-0158-11, 68462-0158-13 |
| Lot numbers | 19251311 |
| Expiration dates | 2027-04-20 |
Product
Ondansetron Orally Disintegrating Tablets, USP, 4mg, 30 Tablets (3 blistercards each containing 10 tablets), Rx only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-157-13
Reason for recall
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0246-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.